FDG-PET/CT imaging for tumor staging and definition of tumor volumes in radiation treatment planning in non-small cell lung cancer

YUANDA ZHENG¹, XIAOJIANG SUN¹, JIAN WANG¹, LINGNAN ZHANG², XIAOYUN DI¹ and YAPING XU¹

Departments of ¹Radiation Oncology and ²Radiology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China

Received June 1, 2013; Accepted December 11, 2013

DOI: 10.3892/ol.2014.1874

Abstract. ¹⁸F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) has the potential to improve the staging and radiation treatment (RT) planning of various tumor sites. However, from a clinical standpoint, questions remain with regard to what extent PET/CT changes the target volume and whether PET/CT reduces interobserver variability in target volume delineation. The present study analyzed the use of FDG-PET/CT images for staging and evaluated the impact of FDG-PET/CT on the radiotherapy volume delineation compared with CT in patients with non-small cell lung cancer (NSCLC) who were candidates for radiotherapy. Intraobserver variation in delineating tumor volumes was also observed. In total, 23 patients with stage I-III NSCLC were enrolled and treated with fractionated RT-based therapy with or without chemotherapy. FDG-PET/CT scans were acquired within two weeks prior to RT. PET and CT data sets were sent to the treatment planning system, Pinnacle, through compact discs. The CT and PET images were subsequently fused by means of a dedicated radiation oncologists on CT (GTV-CT) and PET/CT images (GTV-PET/CT). The resulting volumes were analyzed and compared. For the first phase, two radiation oncologists outlined the contours together, achieving a final consensus. Based on PET/CT, changes in tumor-node-metastasis categories occurred in 8/23 cases (35%). Radiation targeting with fused FDG-PET and CT images resulted in alterations in radiation therapy planning in 12/20 patients (60%) in comparison with CT targeting. The most prominent changes in GTV were observed in cases with atelectasis. For the second phase, the variation in delineating tumor volumes was assessed by four observers. The mean ratio of largest to smallest CT-based GTV was 2.31 (range, 1.01-5.96). The addition of the PET results reduced the mean ratio to 1.46 (range, 1.02-2.27). PET/CT fusion images may have a potential impact on tumor staging and treatment planning. Implementing matched PET/CT results reduced observer variation in delineating tumor volumes significantly with respect to CT only.

Introduction

In locally advanced non-small cell lung cancer (NSCLC), definitive radiation treatment (RT) provides improved disease control and survival rates through high-dose radiation and concurrent administration of systemic drugs. The recent introduction of sophisticated technology, such as three-dimensional conformal RT (3DCRT), promises to improve the cost/benefit ratio of therapy further.

Currently, the issue of precisely identifying the tumor volume remains open; tumor dose escalation and sparing of normal tissue requires the extent of the disease to be precisely identified in each patient. As a result, there is considerable interest in investigating functional imaging, including positron emission tomography (PET) particularly with ¹⁸F-fluorodeoxyglucose (FDG), that provides improved tumor staging, delineation of the target volume, identification of the treatment response and detection of recurrence for a wide range of solid cancer types (1-3). However, due to a lack of anatomical information, a careful correlation must be made between FDG-PET and structural images in order to precisely localize the tumor. A range of image registration strategies allows FDG-PET images to be directly incorporated into computed tomography (CT) images. This allows the complementary strengths of functional (PET) and structural (CT) imaging to be co-registered in a single image set.

A review of the use of PET/CT to define the tumor volume in the RT planning of NSCLC identified 15 previously published studies (4). Only 7 of those included ≥21 patients and only limited studies compared intraobserver variation. The current study is an important contribution that brings under discussion two critical issues with respect to the effect of fused PET/CT on the delineation of gross tumor volume (GTV) in the RT planning of NSCLC patients. These issues are with regard to what extent PET/CT changes the target volume and whether PET/CT reduces interobserver variability in target volume delineation.

Correspondence to: Dr Yaping Xu, Department of Radiation Oncology, Zhejiang Cancer Hospital, 38 Guangji Road, Hangzhou, Zhejiang 310022, P.R. China
E-mail: xuyaping1207@163.com

Key words: positron emission tomography/computed tomography, non-small cell lung cancer, radiotherapy, tumor volume
Materials and methods

Patient characteristics. Between January 2006 and December 2007, 23 consecutive patients with NSCLC were referred for CRT, planned using a fully integrated PET/CT device. All patients were selected for RT, and informed written consent was obtained following the rules of the Zhejiang Cancer Hospital (Hangzhou, China). The clinical stage of the disease varied between I and IIIB, and the median age was 63 years (range, 43-76 years). Patients with a Karnofsky performance status of <80, evidence of distant metastases at initial staging or a requirement for surgical procedures were excluded. The clinical characteristics of the included patients are summarized in Table I. All patients underwent a routine workup, including a clinical examination, fiber endoscopy, contrast-enhanced CT of the chest, liver ultrasound and brain magnetic resonance imaging. The clinical stage was retrospectively defined according to the 2009 Union for International Cancer Control classification (5). No patients were candidates for curative surgery. However, 15 patients were candidates for combined RT and platinum-based chemotherapy and five patients for RT alone. In addition, three patients were diagnosed with metastatic disease based on FDG-PET/CT and received palliative chemotherapy. This study was approved by the Ethical Review Committee, Zhejiang Cancer Hospital (Hangzhou, China). Recommendations from the Helsinki Declaration for biomedical research involving human subjects were followed.

Image acquisition and fusion. All patients underwent PET/CT simulation in the supine position, while immobilized with a customized thermoplastic mask and using the Biograph 16 HI-REZ PET/CT scanner (Siemens Healthcare, Hoffman Estates, IL, USA). The PET component was a high-resolution scanner with a spatial resolution of 4.7 mm and no septa, thus allowing 3D-only acquisitions. The CT component used was the Somatom Sensation 16-slice CT (Siemens Healthcare). The CT scanner was used for attenuation correction of the PET results and for localization of FDG uptake in the PET images. All patients were advised to fast for ≥6 h prior to PET/CT examination. Following injection of ~5 MBq FDG per kg of body weight, the patients were rested for a period of ~60 min in a comfortable chair. Emission images ranging from the proximal femur to the base of the skull were acquired for 2-3 min per bed position. The field of view was 50 cm, with a matrix of 512x512 pixels for CT and 128x128 pixels for PET. The processed images were exhibited in coronal, transverse and sagittal planes. Following image acquisition, PET and CT data sets were sent to the treatment planning system, Pinnacle system (Philips Medical Systems, Milpitas, CA, USA), through compact discs. The CT and PET images were subsequently fused by means of a dedicated RT planning system image fusion tool based on a mutual information algorithm.

Tumor staging and target volume delineation. The clinical staging was analyzed by comparing the PET/CT with the CT observations alone. For clinical purposes, the PET image was always considered as additional information to the CT image for tumor staging or target contouring for treatment planning. The target volumes were outlined by two radiation oncologists with specific experience in lung cancer management according to the guidelines to contour the GTV of the Radiation Therapy Oncology Group 0515 (6). The oncologists were not blinded to each other and worked together to outline the contours, achieving a final consensus. The GTV-CT was defined per CT result as only the gross tumor and any lymph nodes with a cross-sectional diameter of ≥1 cm. Lung window settings were used to contour the primary lesion, and soft tissue windows were used for contouring the lymph nodes. GTV-PET/CT was then defined using fully fused PET/CT imaging as the PET-visualized enhancement of the gross tumor and any lymph node with an average standard uptake value (SUV) of ≥2.5 (regardless of any deficiency in adequate nodal size criteria for malignancy as visualized by CT images alone) or any lymph nodes with a cross-sectional diameter of ≥1 cm on CT. The GTV-PET/CT included PET and CT information. For the second phase, four independent observers were asked to contour and record the GTV-CT and GTV-PET/CT.

Results

Tumor staging. PET/CT imaging led to a change in the tumor-node-metastasis (TNM) stage of 8/23 cases (35%) compared with CT alone (Table II). T-stage changed in 4/23 cases (17%) and N-stage in 7/23 cases (30%).

Target volumes. Of the 20 patients who were not diagnosed with metastatic disease based on FDG-PET/CT planned with 3DCRT, PET/CT clearly altered the radiation therapy volume (>10%) in 12/20 patients (60%) in comparison with CT targeting, which were outlined together by two radiation oncologists. The analyzed volumes for all patients are reported in Table III. PET aided in the ability to distinguish tumors
from atelectasis in all five patients with atelectasis. Atelectasis patients 3, 12, 19 and 20 were cases where the addition of FDG significantly reduced GTV. In atelectasis patient 16, the primary lesion was reduced, but positive mediastinal lymph nodes were detected by PET/CT. Overall, no change in GTV was identified. Unsuspected nodal disease was detected by PET/CT in all 10 patients (two patients with atelectasis of the lung). Patient 10 exhibited a separate tumor focus detected within the same lobe of the lung, and GTV was also increased. The alteration of GTV by PET/CT scan is demonstrated in Fig. 1 in one atelectasis patient and in Fig. 2 in one unsuspected nodal disease patient.

Table II. Change of clinical stage associated with PET/CT in 8/23 patients (35%).

| Case, n | CT stage | PET/CT stage |
|---------|----------|--------------|
| 1       | T1 N0 M0 | T2 N1 M0     |
| 2       | T4 N2 M0 | T3 N3 M0     |
| 3       | T1 N0 M0 | T1 N1 M0     |
| 4       | T2 N0 M0 | T2 N1 M0     |
| 5       | T2 N0 M0 | T2 N1 M0     |
| 6       | T4N2 M0  | T3 N3 M1     |
| 7       | T4 N2 M0 | T2 N2 M1     |
| 8       | T3 N1 M0 | T3 N2 M1     |

CT, computed tomography; PET/CT, positron emission tomography/CT.

Magnitude of interobserver variability. For the second phase, the intraobserver variation in delineating tumor volumes was assessed by four observers. The concordance in GTV of the four observers was increased by the use of PET/CT. The mean ratio of largest to smallest CT-based GTV was 2.31 (range, 1.01-5.96). The addition of the PET results reduced the mean ratio to 1.46 (range, 1.02-2.27). The comparison of

Table III. GTV identified by CT and PET/CT in each case.

| Patients | GTV-CT, cm³ | GTV-PET/CT, cm³ | Ratio |
|----------|-------------|-----------------|-------|
| 1        | 19.9        | 24.3            | 1.22  |
| 2        | 142.2       | 158.4           | 1.11  |
| 3        | 305.2       | 240.3           | 1.27  |
| 4        | 30.5        | 39.7            | 1.30  |
| 5        | 1.5         | 1.5             | 1.00  |
| 6        | 16.1        | 15.1            | 1.07  |
| 7        | 40.0        | 48.3            | 1.21  |
| 8        | 11.4        | 12.3            | 1.08  |
| 9        | 78.0        | 76.3            | 1.02  |
| 10       | 31.8        | 33.4            | 1.05  |
| 11       | 36.3        | 59.9            | 1.65  |
| 12       | 143.7       | 55.3            | 2.60  |
| 13       | 155.0       | 183.9           | 1.19  |
| 14       | 54.5        | 62.1            | 1.14  |
| 15       | 60.1        | 60.9            | 1.01  |
| 16       | 79.5        | 78.7            | 1.01  |
| 17       | 145.9       | 167.0           | 1.14  |
| 18       | 94.8        | 94.2            | 1.01  |
| 19       | 122.1       | 52.6            | 2.32  |
| 20       | 185.5       | 62.9            | 2.95  |

GTV, gross tumor volume-computed tomography; CT, computed tomography; PET/CT, positron emission tomography/CT.
The use of FDG-PET/CT prior to treatment has gained interest in the radiation oncology community in association with a potential improvement in tumor staging, the optimization of treatment strategy and an improved delineation of target volume (7). Preliminary results for numerous tumor loca-

| Patient | CT-GTV, cm³ | PET/CT-GTV, cm³ |
|---------|--------------|-----------------|
| 1       | 27.3         | 25.9            |
| 2       | 152.6        | 142.2           |
| 3       | 349.3        | 239.0           |
| 4       | 44.7         | 45.1            |
| 5       | 1.7          | 1.7             |
| 6       | 16.2         | 16.1            |
| 7       | 59.0         | 57.0            |
| 8       | 11.3         | 11.4            |
| 9       | 78.6         | 68.0            |
| 10      | 34.8         | 31.8            |
| 11      | 75.5         | 64.0            |
| 12      | 224.7        | 87.5            |
| 13      | 145.8        | 155.0           |
| 14      | 67.5         | 34.5            |
| 15      | 80.1         | 60.1            |
| 16      | 232.6        | 93.5            |
| 17      | 120.9        | 140.9           |
| 18      | 71.0         | 94.8            |
| 19      | 180.5        | 59.1            |
| 20      | 186.1        | 75.1            |

CT-GTV, computed tomography-gross tumor volume; PET/CT-GTV, positron emission tomography/CT-GTV; Obs, observer.
tions, including the head and neck, lung, esophagus, rectum, anal canal and pancreas, have been reported in a number of previous literature studies (8-12). Certain studies concerning the advantage of PET/CT fusion have been previously reported for radiation planning of patients with NSCLC (13-15).

In the current study, based on PET/CT, changes in TNM stage occurred in 8/23 cases (35%). Similar results were reported by Bradley et al (16), where 26 patients were enrolled and PET/CT fusion was found to alter the TNM categories in 31% of patients (8/26). In the present study, three patients were diagnosed with metastatic disease based on PET-PET and received palliative radiation therapy. To date, it appears that the best benefit from FDG-PET in NSCLC is the evaluation of the cancer extent. FDG-PET/CT identifies patients with tumor spread not detected by standard methods in ~20% of the cases (17).

In the current study, the effect of PET/CT on the delineation of GTV was evaluated considering the PET information in addition to that of CT. PET aided the ability to distinguish tumors from atelectasis in all five patients with atelectasis. Unsuspected nodal disease was detected by PET in 10 patients, and one patient exhibited a separate tumor focus detected within the same lobe of the lung. Previous studies have shown that fused PET and CT alters ~50% of the GTV delineation compared with CT targeting alone, as observed by visual evaluation or using specific mathematical algorithms, such as a fixed SUV or threshold. The presence of atelectasis, which appears easier to differentiate from tumors with the use of combined PET/CT information, often leads to a significant decrease in GTV (20-24). Since routine elective nodal irradiation is often omitted in NSCLC, accurate identification of the involved nodal areas is pivotal in modern treatment planning with curative intent. A number of previous studies have shown significant changes in GTV volume due to the inclusion or exclusion of nodal areas compared with CT-alone GTV (25-27). In a prospective clinical study, De Ruyscher et al (28) evaluated the patterns of recurrence following FDG-PET-based selective mediastinal node irradiation in 44 patients with NSCLC. The rationale of the study was the higher diagnostic accuracy of FDG-PET on mediastinal lymph node areas. Only one case of nodal recurrence was reported from the 44 patients selectively irradiated on the FDG-avid areas of the mediastinum.

In the second part of the present study, the results showed that FDG-PET reduced the ratio of largest to smallest GTV in the majority of cases (14/20). The concordance in treatment planning of the four observers was increased by the use of PET/CT. The mean ratio of largest to smallest CT-based GTV was 2.31 (range, 1.01-5.96). The addition of the PET results reduced the mean ratio to 1.46 (range, 1.12-2.27). Atelectasis patients 3, 12, 16, 19 and 20 were cases where the addition of FDG evidently reduced interobserver variability. For patient 19 (Fig. 1), it was difficult to distinguish atelectasis of the lung from the tumor using CT alone; FDG clarified the location of the tumor and aided the determination of a consistent boundary. For patient 15, FDG aided the ability of the four observers to achieve a more consistent conclusion concerning the presence of nodal disease. In the majority of cases where the addition of FDG appeared to increase interobserver variability, the increase was minor. However, in patient 11, the addition of FDG did not significantly reduce variability. The SUV of FDG uptake was <2.5 in the lymph nodes with a cross-sectional diameter of 1 cm on CT, which three of the four observers interpreted as being positive lymph nodes. However, the fourth observer interpreted the FDG uptake in the lymph nodes as not indicating tumor metastasis.

The majority of previous studies, as well as the present study, may promote certain criticism, as there is an uncertain correlation between the PET/CT observations and the real tumor extension, which may only be precisely assessed on the surgical specimen. In the current study, only one case exhibited a cytological correlation with lymph nodes; PET/CT overestimated the lymph node tumor extension. An additional case exhibited a cytological correlation with the primary lesion, however, it was difficult to identify tumor necrosis. FDG uptake was identified in the area of the apparent tumor necrosis, which three of the four observers interpreted as being indicative of tumor. However, the fourth observer interpreted the borderline FDG uptake in the area as not indicating tumor. This difference in interpretation of FDG uptake led to a large degree of interobserver variability in the PET/CT-GTV. The correlation between tumor delineation on PET compared with pathology was investigated by Faria et al (29), who compared FDG-PET/CT image fusion with the histopathology of 32 patients. The CT-determined stage was altered by the pathological examination in 22/32 patients (69%), while the PET-determined stage was altered in 16/32 patients (50%). The N-stage was associated with the most significant alterations. The TNM stage was altered by PET in 15/32 patients (44%) compared with CT alone, however, only seven of these alterations were confirmed by the pathological observations.

The consistency of target delineation on PET images is an issue that remains unclear. The literature has shown GTV contouring with FDG-PET to be varied, but these data have typically been based on the SUV. In the present study, an average SUV of ≥2.5 was adopted, consistent with the SUV proposed for lung cancer by another study (30).

The present study shows that FDG-PET/CT images for primary NSCLC exhibit a potential impact on disease staging and treatment planning. A clinical stage variation was observed in 35% of cases (8/23). Based on the results from the present study and from previous literature, the future scenario of the imaging for RT of NSCLC may include the use of functional imaging, such as FDG-PET/CT, with the aim of characterizing the biological features of the tumor and optimizing the use of highly conformal and biologically effective RT.

Acknowledgements

The present study was supported by a grant from the National Natural Science Foundation of China (No. 81272505/H1610).

References

1. Abramyuk A, Appold S, Zöphel K, et al: Quantitative modifications of TNM staging, clinical staging and therapeutic intent by FDG-PET/CT in patients with non small cell lung cancer scheduled for radiotherapy - a retrospective study. Lung Cancer 78: 148-152, 2012.
2. Vaidya M, Creach KM, Frye I, et al: Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer. Radiother Oncol 102: 239-245, 2012.
3. Satoh Y, Nambu A, Onishi H, et al: Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy. Eur J Radiol 51: 3530-3534, 2012.

4. Greco C, Rosenzweig K, Cascini GL and Tamburrini O: Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer 57: 125-134, 2007.

5. Edge SB, Byrd DR, Compton CC, et al, (eds). AJCC Cancer Staging Manual. 7th ed. Springer Verlag, New York, NY, 2009.

6. Bradley J, Bae K, Choi N, et al: A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515. Int J Radiat Oncol Biol Phys 82: 435-441, 2012.

7. Paulino AC, Thorstad WL and Fox T: Role of fusion in radiotherapy treatment planning. Semin Nucl Med 33: 2338-2343, 2003.

8. Abramyan A, Appold S, Zöpfel K, et al: Modification of staging and treatment of head and neck cancer by FDG-PET/CT prior to radiotherapy. Strahlenther Onkol 189: 197-201, 2013.

9. Mac Manus MP and Hicks RJ: The role of positron emission tomography/computed tomography in radiation therapy planning for patients with lung cancer. Semin Nucl Med 42: 308-319, 2012.

10. Buijsen J, van den Bogaard J, van der Weide H, et al: FDG-PET-CT reduces the interobserver variability in rectal tumor delineation. Radiother Oncol 102: 371-376, 2012.

11. Van Baardwijk A, Baumert B, Bosmans G, et al: The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev 32: 245-260, 2006.

12. Pakzad F, Groves A and Eil PJ: The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med 36: 248-256, 2006.

13. Fleckenstein J, Hellwig D, Kremp S, et al: F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial. Int J Radiat Oncol Biol Phys 81: e283-e289, 2012.

14. Rodríguez N, Sanz X, Trampal C, et al: 18F-FDG PET definition of gross tumor volume for radiotherapy of lung cancer: is the tumor uptake value-based approach appropriate for lymph node delineation? Int J Radiat Oncol Biol Phys 78: 659-666, 2010.

15. Biehl KJ, Kong FM, Dehdashti F, et al: 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? J Nucl Med 47: 1808-1812, 2006.

16. Bradley J, Thorstad WL, Mutic S, et al: Impact of FDG-PET on radiation therapy volume delineation in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 59: 78-86, 2004.

17. MacManus MP, Hicks RJ, Matthews JP, et al: High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: Implications for radical radiotherapy. Int J Radiat Oncol Biol Phys 50: 287-293, 2001.

18. Hong R, Halamia J, Bova D, et al: Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning. Int J Radiat Oncol Biol Phys 67: 720-726, 2007.

19. Dainsje JF, Sibomana M, Bös A, et al: Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background rations: influence of reconstruction algorithms. Radiother Oncol 69: 247-250, 2003.

20. Giraud P, Grahek D, Montravers F, et al: CT and (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys 49: 1249-1257, 2001.

21. Nestle U, Walter K, Schmidt S, et al: 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 44: 593-597, 1999.

22. Deniaud-Alexandre E, Touboul E, Lerouve D, et al: Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 63: 1432-1441, 2005.

23. Cerninck IF, Dizendorf E, Baumert BG, et al: Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 57: 853-863, 2003.

24. Ceresoli GL, Cattaneo GM, Castellone P, et al: Role of computed tomography and [18F] fluoro-deoxyglucose positron emission tomography image fusion in conformal radiotherapy of non-small cell lung cancer: a comparison with standard techniques with and without elective nodal irradiation. Tumori 93: 88-96, 2007.

25. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al: The impact of (18)F-fluoro-2-deoxy-D-glucose1432 positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 55: 317-324, 2000.

26. van Der Wel A, Nijsten S, Hochstenbag M, et al: Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small cell lung cancer: a modeling study. Int J Radiat Oncol Biol Phys 61: 649-655, 2005.

27. Nestle U, Hellwig D, Schmidt M, et al: 2-Deoxy-2-[18F] fluoro-D-glucose positron emission tomography in target volume definition for radiotherapy of patients with non-small-cell lung cancer. Mol Imaging Biol 4: 257-263, 2002.

28. De Ruyscher D, Wanders S, van Haren E, et al: Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 62: 988-994, 2005.

29. Faria SL, Menard S, Devic S, Sirois C, et al: Impact of FDG-PET/CT on radiotherapy volume delineation in non-small-cell lung cancer and correlation of imaging stage with pathologic findings. Int J Radiat Oncol Biol Phys 70: 1035-1038, 2008.

30. Ashamalla H, Rafia S, Parikh K, et al: The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys 63: 1016-1023, 2005.